Abivax

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

Retrieved on: 
Jeudi, janvier 4, 2024

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

Key Points: 
  • Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer
    Paul Gineste brings 25 years of experience in clinical development and strategy with leading international pharmaceutical and biotech companies.
  • Recently, Paul served as Vice President, Clinical Operations at Abivax, where he led the development of drug candidates from discovery through global Phase 3 programs.
  • Paris, France, January 4, 2024 - Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Paul Gineste as Chief Development Officer (CDO), effective January 1, 2024.
  • Scott Filosi, CEO of Evexta Bio, said: "I am delighted to welcome Paul as the new Chief Development Officer of Evexta Bio.

EQS-News: Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Samedi, décembre 30, 2023

PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that management will be holding meetings with investors and presenting a corporate overview at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place in New York on November 28-30, 2023.

Key Points: 
  • PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that management will be holding meetings with investors and presenting a corporate overview at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place in New York on November 28-30, 2023.
  • To enter the live webcast, please click here .
  • The link to the live webcast of the presentation may also be accessed under “News & Events” on the Investor Relations section of the Abivax website at www.abivax.com .
  • A replay of the webcast will be available on the Company’s website for approximately three months.

Nasdaq Welcomes 125 IPOs and 26 Exchange Transfers in 2023

Retrieved on: 
Jeudi, décembre 14, 2023

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that in 2023 it welcomed 125 initial public offerings (IPOs), raising a total of $13 billion. A total of 100 operating companies and 25 SPACs listed on Nasdaq this year, representing an 86%-win rate of Nasdaq-eligible IPOs in the U.S. market, and extending Nasdaq’s leadership for the fifth consecutive year. In addition to IPOs, there were 26 exchange transfers to Nasdaq, totaling $374 billion in market value.

Key Points: 
  • NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that in 2023 it welcomed 125 initial public offerings (IPOs), raising a total of $13 billion.
  • In addition to IPOs, there were 26 exchange transfers to Nasdaq, totaling $374 billion in market value.
  • Three of the top five largest IPOs by proceeds raised listed on Nasdaq, including Arm, Instacart and Nextracker.
  • More market value switched to Nasdaq than any other U.S. exchange: Nasdaq welcomed 26 switches in 2023, representing $374 billion in market value, including the largest switch to Nasdaq of all time, Linde, as well as DoorDash and Cooper Companies.

Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Mardi, novembre 14, 2023

PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that management will be holding meetings with investors and presenting a corporate overview at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place in New York on November 28-30, 2023.

Key Points: 
  • PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that management will be holding meetings with investors and presenting a corporate overview at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place in New York on November 28-30, 2023.
  • To enter the live webcast, please click here .
  • The link to the live webcast of the presentation may also be accessed under “News & Events” on the Investor Relations section of the Abivax website at www.abivax.com .
  • A replay of the webcast will be available on the Company’s website for approximately three months.

EQS-News: Abivax announces the resumption of its liquidity contract

Retrieved on: 
Jeudi, décembre 14, 2023

Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces the resumption, as of today, of its liquidity contract and the end of the stabilization period.

Key Points: 
  • Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces the resumption, as of today, of its liquidity contract and the end of the stabilization period.
  • The liquidity contract was entered into with TSAF on June 26, 2015, and suspended in the context of the initial public offering of Abivax shares in the form of ADS on the Nasdaq Global Market.
  • Following the stabilization activities carried out since October 20, 2023, the stabilization period has ended on November 20, 2023.
  • As of November 20, 2023, the following means are allocated to the liquidity account for the execution of this contract:
    11,257 Abivax shares held on behalf of Abivax,

Rapport Therapeutics Appoints Chief Financial Officer

Retrieved on: 
Lundi, octobre 30, 2023

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231030359557/en/
    “We are thrilled to welcome Troy to the Rapport executive team during this time of rapid progress for our company,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • Most recently, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings.
  • Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals.

EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Retrieved on: 
Jeudi, octobre 26, 2023

Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Key Points: 
  • Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
    The issuer is solely responsible for the content of this announcement.
  • Offering”) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement”, and together, the “Global Offering”).
  • The Company’s ordinary shares are listed on the regulated market of Euronext Paris (“Euronext Paris”) under the symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris

Retrieved on: 
Jeudi, octobre 26, 2023

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • PARIS, France, October 20, 2023 – 03:45 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on Euronext in Paris (“Euronext Paris”) as from 4:20 p.m. CEST.
  • Trading of the ordinary shares of Abivax was halted at the request of the Company on October 20, 2023 from 9:00 a.m. CEST in connection with its previously announced initial public offering of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Market (the “Global Offering”), in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company’s ADSs on the Nasdaq Global Market.

EQS-News: Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market

Retrieved on: 
Jeudi, octobre 26, 2023

Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).

Key Points: 
  • Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).
  • The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share in the European Private Placement.
  • All of the ADSs and ordinary shares in the Global Offering were offered by Abivax.
  • Morgan Stanley and Leerink Partners acted as joint global coordinators for the Global Offering and joint bookrunners for the U.S. Offering.

EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023

Retrieved on: 
Lundi, octobre 2, 2023

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)
    Moderated poster presentation highlighting correlation of pharmacokinetic (PK) parameters with enhanced expression of a single microRNA, miR-124, in blood of obefazimod-treated UC patients
    PARIS, France, October 2, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that three scientific abstracts on its lead drug candidate, obefazimod, will be presented during the United European Gastroenterology (UEG) Week meeting, October 14-17, 2023, in Copenhagen, Denmark.
  • “We continue to be encouraged by the emerging clinical profile of obefazimod based on the 96-week efficacy and safety data from our Phase 2b open-label maintenance study,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • “With the presentation of this new data and the underlying novel mechanism of action, obefazimod has the potential to advance the treatment paradigm for people living with ulcerative colitis.”
    For more information on the Abivax clinical program and company updates, please visit Abivax’s UEG booth at C2-32 or see the conference program at the UEG website .